Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.60 |
| ▸ | KIT | P10721 | 3/20 | 0.60 |
| ▸ | FLT4 | P35916 | 3/20 | 0.60 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.60 |
| ▸ | ILK | Q13418 | 1/20 | 0.60 |
| ▸ | FLT1 | P17948 | 7/20 | 0.48 |
| ▸ | CSF1R | P07333 | 2/20 | 0.47 |
| ▸ | CIT | O14578 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | HLA-A | P04439 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | FRK | P42685 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.46 |
| ▸ | STK3 | Q13188 | 1/20 | 0.46 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.46 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6479719 | 0.99 | KDR (0.59) | KDRPDGFRBKITFLT4MAP3K20 | |
| SCHEMBL6497078 | 0.95 | KDR (0.58) | KDRPDGFRBKITFLT4MAP3K20 | |
| SCHEMBL6474476 | 0.89 | KDR (0.76) | KDRPDGFRBKITFLT4MAP3K20 | |
| SCHEMBL2202245 | 0.88 | KDR (0.57) | KDRPDGFRBKITFLT4MAP3K20 | |
| SCHEMBL2200373 | 0.86 | KDR (0.80) | KDRPDGFRBKITFLT4MAP3K20 | |
| SCHEMBL6497045 | 0.85 | KDR (0.50) | KDRPDGFRBKITFLT4MAP3K20 | |
| SCHEMBL12233260 | 0.84 | KDR (0.47) | KDRPDGFRBKITFLT4MAP3K20 | |
| SCHEMBL6482081 | 0.84 | KDR (0.69) | KDRPDGFRBKITFLT4MAP3K20 | |
| SCHEMBL6482221 | 0.84 | KDR (0.53) | KDRPDGFRBKITFLT4MAP3K20 | |
| SCHEMBL6600180 | 0.83 | KDR (0.52) | KDRPDGFRBKITFLT4MAP3K20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903101-B1 | Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-07 | — | — | US | claimed |
| US-20050019424-A1 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives | BAYER HEALTHCARE LLC | 2005-01-27 | — | — | US | claimed |
| EP-1467736-A2 | ANTI-ANGIOGENESIS COMBINATION THERAPIES COMPRISING PYRIDAZINE OR PYRIDINE DERIVATIVES | Bayer Pharmaceuticals Corporation (US) | 2004-10-20 | — | — | EP | claimed |
| EP-1208096-B1 | SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER AG (US) | 2004-04-28 | — | — | EP | claimed |
| WO-2003059354-A2 | ANTI-ANGIOGENESIS COMBINATION THERAPIES COMPRISING PYRIDAZINE OR PYRIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-24 | — | — | WO | claimed |
| EP-1208096-A1 | SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Bayer Corporation (US) | 2002-05-29 | — | — | EP | claimed |
| WO-2001010859-A1 | SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORPORATION (US) | 2001-02-15 | — | — | WO | claimed |
| US-6903101-B1 | Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1208096-B1 | SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER AG (US) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019424-A1 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives | KDR, FLT4, FLT1 | KDR 1/4885PDGFRB 7/4885KIT 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.